Analyst Ranking
Bottom 3%
#4750 out of 4868 analysts
Average Return
-25.62%
Win Rate
24%6 out of 25
Risk vs Reward
Poor
Good

John Sourbeer's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Catalent IncCTLT
+33.32%$43.85$58.46
2023-06-12 -
2024-02-06
Strong Buy
Catalent IncCTLT
+19.35%$48.98$58.46
2023-08-29 -
2024-02-06
Strong Buy
Icon PLCICLR
+18.89%$215.91$256.69
2022-09-06 -
2023-09-06
Strong Buy
Abbott LaboratoriesABT
+18.40%$99.25$117.51
2020-07-16 -
2021-07-16
Strong Buy
Abbott LaboratoriesABT
+3.72%$109.99$114.08
2022-07-26 -
2023-07-26
Strong Buy

John Sourbeer Analyst Color

Get additional color on John Sourbeer's coverage of popular stocks

John Sourbeer's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Cryoport IncCYRX
6Strong Buy$11.00+97.13%Maintains
a month ago
Stevanato Group SpaSTVN
2Hold$23.50+12.66%Maintains
2 months ago
Quidelortho CorpQDEL
3Hold$45.00+61.93%Maintains
3 months ago
Qiagen NvQGEN
4Hold$48.00+12.28%Maintains
3 months ago
West Pharmaceutical Services IncWST
3Strong Buy$390.00+84.58%Upgrades
5 months ago
Pacific Biosciences Of California IncPACB
3Hold$2.00+80.18%Downgrades
6 months ago
Illumina IncILMN
3Hold$145.00+86.86%Maintains
6 months ago
Singular Genomics Systems IncOMIC
2Hold$15.00N/AMaintains
a year ago
Medpace Holdings IncMEDP
4Strong Buy$480.00N/AMaintains
a year ago
Akoya Biosciences IncAKYA
2Strong Buy$7.50N/AMaintains
a year ago
Bruker CorpBRKR
3Strong Buy$102.00N/AMaintains
a year ago
Catalent IncCTLT
4Hold$63.50N/ADowngrades
a year ago
Nanostring Technologies IncNSTGQ
2Strong Buy$2.50N/AMaintains
2 years ago
10x Genomics IncTXG
1Hold$50.00N/AInitiates Coverage On
2 years ago
Syneos Health IncSYNH
1Hold$68.00N/AInitiates Coverage On
3 years ago
Icon PLCICLR
1Strong Buy$270.00N/AInitiates Coverage On
3 years ago
Abbott LaboratoriesABT
2Strong Buy$128.00N/AMaintains
3 years ago
Zymergen IncZY
2Hold$4.00N/AMaintains
3 years ago
Ortho Clinical Diagnostics Holdings PLCOCDX
1Strong Buy$23.00N/AInitiates Coverage On
4 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.